Alternative Systemic Therapies for Photocontact Dermatitis

Introduction to Alternative Therapies

The American Academy of Dermatology recommends cyclosporine as the preferred first-line alternative when methotrexate cannot be given for photocontact dermatitis, followed by azathioprine as a second-line option 1, 2

Cyclosporine is effective and recommended as a treatment option for patients with refractory dermatitis when conventional topical treatments fail, with a dosing range of 3-6 mg/kg per day 1, 2
The initial dose of cyclosporine should be started at 3-6 mg/kg per day, divided into two doses, with consideration of a test dose initially, then checking CBC in 5-6 days 1, 2
The dose of cyclosporine should be adjusted to the minimal effective dose once response is attained, with ongoing monitoring of creatinine levels 1, 2

Azathioprine is recommended as a systemic agent for the treatment of refractory dermatitis and has demonstrated efficacy in contact dermatitis, with a dosing range of 1-3 mg/kg per day 1, 2
Dosing of azathioprine may be guided by TPMT enzyme activity testing, with consideration of starting at lower doses and titrating up based on response and tolerance 1, 2

Dupilumab receives a strong recommendation as first-line systemic therapy for moderate-to-severe inflammatory dermatitis, with a dosing regimen of 600 mg loading dose, then 300 mg subcutaneously every 2 weeks 3, 4
Upadacitinib, abrocitinib, and baricitinib all receive strong recommendations for the treatment of severe, refractory dermatitis, particularly in patients who have failed other systemic therapies or when use of those therapies is inadvisable 3, 4

Systemic corticosteroids should be avoided for chronic management of contact dermatitis, with their use exclusively reserved for acute, severe exacerbations and as short-term bridge therapy to other systemic, steroid-sparing therapy 1, 2, 3

The American Academy of Dermatology recommends a clinical decision algorithm for the treatment of photocontact dermatitis, starting with cyclosporine 3-6 mg/kg per day if renal function is normal and blood pressure is controlled, followed by azathioprine 1-3 mg/kg per day if cyclosporine is contraindicated or not tolerated 1, 2
For severe, refractory disease, consideration should be given to dupilumab or JAK inhibitors, particularly if there is significant quality of life impairment 3, 4

All immunomodulatory agents require careful monitoring for adverse effects and should be adjusted to the minimal effective dose once response is achieved, with continuation of adjunctive topical therapies to minimize the dose and duration of systemic agents 1, 2